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Purpose: To report three low-passage cell lines from primary choroidal melanoma with metastatic outcome, which were
stable for cytogenetic patterns and expression profiles of the primary melanoma.
Methods: In patients with choroidal melanoma, transscleral fine needle aspiration biopsy (FNAB) was performed
immediately before plaque placement for 125iodine brachytherapy or immediately after enucleation. Cells were examined
for cytopathology, evaluated by fluorescence in-situ hybridization (FISH) for the centromere of chromosome 3, analyzed
by 250K whole genome Mapping Array and U133 plus 2.0 Expression Array, and placed in cell culture. At passage 3,
the cell lines were analyzed by Mapping Array and Expression Array.
Results: Three cell lines were propagated from primary choroidal melanomas in three patients who subsequently
developed metastasis. Two cell lines were stable for the entire chromosomal aberration pattern of the respective primary
tumor. In the third, necrotic material from the biopsy prevented further analysis, yet resulted in a stable cell line. Each
cell line had chromosome 3 loss, 6q loss, 8p loss, multiple 8q gain, and 16q loss. Additionally, two cell lines had
chromosome 6p gain. Two cell lines had RNA expression profiles similar to the respective primary tumors; the third cell
line had a similar RNA expression profile relative to the other two cell lines.
Conclusions: FNAB of primary choroidal melanomas resulted in highly characterized, low-passage cell lines, which were
stable for the cytogenetic patterns and expression profiles found in the primary tumor. These cell lines represent novel
tools for the study of metastatic choroidal melanoma biology.
Choroidal melanoma (melanoma arising primarily from
the ciliary body or choroid) is the most common primary
intraocular  malignancy  in  adults.  Despite  treatment  with
brachytherapy, external beam radiation or enucleation, long-
term follow-up is associated with melanoma-related death in
approximately 50% of patients [1].
Most strongly correlated with increased risk of metastasis
are cytogenetic aberrations and gene expression abnormalities
in melanoma cells [2-5]. Loss of one copy of chromosome 3
(monosomy 3), loss of one copy of chromosome 8p and class
II gene expression profile are most strongly associated with a
high-risk of metastasis [4,6-10].
Melanoma  cytogenetic  abnormalities  provide
information regarding the fundamental molecular biology of
choroidal melanoma and may uncover potential genes for
targeted therapy [11,12]. Recognizing the potential value of
studying melanoma cytogenetic aberrations and associated
gene  expression,  this  report  presents  development  and
characterization  of  low-passage  choroidal  melanoma  cell
lines that were stable for the cytogenetic patterns and gene
expression profiles found in primary choroidal melanomas
that resulted in metastatic disease.
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METHODS
All studies were performed in accordance with the United
States Health Insurance Portability and Accountability Act
(HIPAA) of 1996. All participants gave informed consent and
all  studies  were  approved  by  the  Office  of  the  Human
Research Protection Program (Institutional Review Board) of
the University of California, Los Angeles, Los Angeles, CA.
Tissue  collection:  In  patients  with  primary  choroidal
melanoma and no clinical evidence of metastasis, transscleral
fine  needle  aspiration  biopsy  (FNAB)  was  performed
immediately  before  plaque  placement  for  125iodine
brachytherapy or immediately after enucleation. As described
elsewhere, cells obtained from the biopsy were examined for
cytopathology,  evaluated  by  fluorescence  in-situ
hybridization (FISH) for the centromere of chromosome 3,
analyzed by 250K Mapping Array (Affymetrix, Santa Clara,
CA) for chromosomal copy number variation, U133 plus 2.0
Arrays (Affymetrix) for gene expression, and placed in cell
culture [11-13].
Cell culture: Triturated biopsy cells were cultured in a
growth medium of DMEM, 10% human AB serum, 5 µg/ml
bovine insulin and glutamine-pen-strep at 37 °C, 7% CO2.
Primary cultures were seeded in 12.5 cm2 vented flasks and
grown to confluency (about 12 weeks) replacing half of the
medium every 3 days.
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607These spontaneous cultures were expanded into 75 cm2
flasks and evaluated at passage 3. Briefly, trypsinized cells
were  stabilized  in  RNAprotect  Cell  Reagent  (Qiagen,
Valencia, CA) and analyzed by 250K Mapping Array and
U133 plus 2.0 Expression Array (Affymetrix) as described
hereafter. Beginning at passage 3, portions of the cell lines
were cryogenically preserved for use in future studies and
passaged in cell culture to document the characteristics of
continued proliferation.
Nucleic acid analyses: Genomic DNA and total RNA
were sequentially isolated from trypsinized cell cultures using
an AllPrep DNA/RNA Mini Kit (Qiagen). Isolated DNA was
quantified using a NanoDrop ND-1000 Spectrophotometer
(NanoDrop,  Wilmington,  DE).  No  DNA  sample  was
subjected to whole genome amplification techniques. DNA
copy number was assessed using GeneChip Human 250K
NSPI  Mapping  Arrays  (Affymetrix).  Probe  preparation,
hybridization,  and  reading  were  performed  by  the  UCLA
DNA  Microarray  Core  according  to  the  standard  96-well
protocol published by Affymetrix. Copy number variation
was  computed  using  Genome  Console  software  from
Affymetrix [11].
RNA was quantified on a NanoDrop Spectrophotometer
and analyzed on a 2100 Bioanalyzer (Agilent, Santa Clara,
CA) for integrity. RNA had an A260/280 ratio of >1.90 and
RNA integrity number (RIN) of 8.5 or higher as determined
by the 2100 Bioanalyzer. Prepared RNA was hybridized to
GeneChip  Human  Genome  U133  Plus  2.0  Arrays
(Affymetrix) at the UCLA DNA Microarray Core Facility
using the standard Affymetrix protocol.
GNAQ mutation: Additionally, the nucleotide sequence
of exon 5 of the guanine nucleotide binding protein (G protein)
q  polypeptide  (GNAQ)  was  determined  for  both  cell  line
genomic  DNA  and  available  germ  line  DNA  from  blood
samples via PCR and sequencing on an ABI 3130 Genetic
Analyzer using BigDye 2.0 chemistry (Life Technologies,
Carlsbad, CA), and intronic sequence primers 5′-TTC CCT
AAG TTT GTA AGT AGT GC-3′ and 5′-AGA AGT AAG
TTC ACT CCA TTC C-3′ encompassing exon 5 of GNAQ.
RESULTS
Cell cultures from choroidal melanomas with chromosome 3
loss (monosomy 3) showed variable propagation (Table 1).
Among choroidal melanomas with chromosome 6p gain in the
absence  of  chromosome  3  loss,  all  cell  cultures  failed  to
propagate under the growth conditions employed. Each of the
three cell lines were derived from two pooled fine needle
aspirates containing approximately 110, 500, or 350 viable
cells for MEL20–06–039, MEL20–06–045, or MEL20–07–
070, respectively, as determined by counts of adherent cells
obtained 24 h after initial seeding in a 12.5 cm2 flask. In each
case  epithelioid  morphology  was  initially  observed.
Macrophages  and  erythrocytes  were  present  initially,  but
rapidly  degraded.  No  fibroblasts  were  observed.  At
confluency, each culture was expanded into a 75 cm2 flask.
All subsequent passages were split 1:3 in 75 cm2 flasks with
1×107 cells removed and aliquoted for cryopreservation.
The three characterized cell lines with monosomy 3 were
from  patients  with  choroidal  melanoma  who  developed
clinical evidence of melanoma metastasis <1.5 years after
primary melanoma diagnosis and treatment; all three patients
subsequently died from liver failure due to metastatic disease.
All three cell lines demonstrated stable propagation through
at least passage 6 over a period of 2.5 years. Two of the three
cell lines persisted in melanin production beyond passage 6
and none of the cultures exhibited contact inhibition in over-
growth conditions (Figure 1).
Cytogenetically, two of the three cell lines (MEL20–06–
039  and  MEL20–07–070)  demonstrated  the  chromosomal
aberration  pattern  present  in  the  respective  primary
melanoma, including monosomy 3, 6q loss, 8p loss, multiple
8q gain and 16q loss (Figure 2). The third cell line (MEL20–
06–045), derived from a biopsy that showed necrotic material,
had  a  chromosomal  aberration  pattern  that  was  nearly
identical  with  the  other  two  cell  lines.  Additionally,  the
MEL20–06–045 cell line and both the MEL 20–07–070 cell
line  and  primary  tumor  exhibited  chromosome  6p  gain.
Moreover, two of the cell lines (MEL20–06–039 and MEL20–
07–070) had RNA expression array characteristics similar to
the respective primary tumor for the 25 most overexpressed
and the 20 most under-expressed genes from a comparative
gene list composed of genes most overexpressed and under-
expressed in an integrated analysis of choroidal melanoma
with chromosome 3 loss versus 6p gain in the absence of
chromosome 3 loss (Figure 3A,B) [11]. The third cell line
(MEL20–06–045) had a similar profile of gene expression
TABLE 1. CHOROIDAL MELANOMA CELL CULTURES.
59 Melanomas with Chromosome 3 Loss Number
Successful propagation and characterization of cell lines 3 (5%)
Successful early propagation but not yet characterized 6 (10%)
Failure to propagate beyond first passage 40 (68%)
Failure to propagate 10 (17%)
42 Melanomas with Chromosome 6p Gain/Disomy 3 Number
Failure to propagate 42 (100%)
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608Figure 1. Phase contrast photomicrographs of cell lines in subconfluent and overgrowth conditions. At passage 3, cell lines MEL20–06–039
(A and B), MEL20–06–045 (C and D) and MEL20–07–070 (E and F) show early stage propagation (A, C, and E) and late stage confluent
propagation with heaped up cells and no evidence of contact inhibition (B, D, and F). Melanin production is evident in two cell lines (MEL20–
06–045 and MEL20–07–070). Original magnification (A, C, E) 200×, (B, D, F) 100×. Scale bar is 30 µm.
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609when compared to the two primary melanomas and the other
two cell lines (Figure 3C).
Sequence  analysis  of  exon  5  of  GNAQ  demonstrated
heterozygous mutations in codon 209 in two of the three
cultures (resulting in either Q209L or Q209P) and wild-type
sequence in the third culture (Figure 4). Codon 209 sequence
analysis of blood samples from the patients with Q209L and
wild-type sequence revealed only wild-type sequence in both
patients. No blood sample was available from the patient with
Q209P gene mutation.
DISCUSSION
This report presents for the first time, to our knowledge, cell
lines characterized by microarray and grown from choroidal
melanoma in patients who developed clinical metastases. Cell
line characterization at passage 3 with 250K Mapping Arrays
showed that each of the three cell lines and the two respective
primary melanomas had common cytogenetic characteristics
for monosomy 3, 6q loss, 8p loss, multiple 8q gain, and 16q
loss. Two of the cell lines, MEL20–06–045 and MEL20–07–
070 also demonstrated gains in chromosome 6p. Analysis of
gene expression with U133 Plus 2.0 Arrays showed that two
of the cell lines expressed gene characteristics similar to the
respective primary melanoma for the 25 most overexpressed
genes and the 20 most under-expressed genes in a comparative
gene list composed of genes most overexpressed and under-
expressed in an integrated analysis of choroidal melanoma
with chromosome 3 loss versus 6p gain in the absence of
chromosome 3 loss [11]; the third cell line had a profile of
gene expression similar to the two primary melanomas and
the other two cell lines. Potentially relevant functional classes
of  biologic  activity  include  G-protein  coupled  signaling,
calcium response pathways, cell adhesion marker expression,
retinoic  acid  response  pathways  and  regulation  of
palmitoylation [11].
Furthermore, sequence analysis from exon 5 of GNAQ
demonstrated heterozygous mutation of codon 209 in two of
the three cell lines and the wild-type sequence in the third.
GNAQ codon 209 mutations in choroidal melanoma have
been  shown  to  be  important  in  primary  melanoma  tumor
development [14,15].
Choroidal melanoma cell lines derived from melanomas
that progressed to clinical metastases and patient death with
cytogenetic  characteristics  and  gene  expression  profiles
closely corresponding to the respective primary melanoma are
important for at least two reasons. First, there is no animal
model  of  spontaneous  uveal  melanoma  that  accurately
replicates the course of the human disease [16]. Transgenic
animal  models  of  human  disease  do  not  reproduce  the
histiogenesis  of  human  melanoma  and  animal  melanoma
differs substantially from human uveal melanoma [17,18].
Second, cancer evolves through a process of step-wise
accumulation of genetic alterations that result in uncontrolled
cell proliferation and a lack of response to normal apoptotic
stimuli. Genetic alterations include deletions, duplications/
amplifications, translocations and point mutations that cause
loss-of-function or gain-in-function and lead to altered protein
expression. Availability of cell lines that closely correspond
to the cells of metastasis-causing choroidal melanomas may
serve as important in vitro models for the study of melanoma
biology [19].
Characterization of the choroidal melanoma cell lines in
this report extends the initial attempt at uveal melanoma cell
culture by Kirby [20] in 1929, the report of six continuous cell
lines from choroidal and ciliary body melanomas by Albert et
al. [21]. in 1984 and subsequent reports of cell lines derived
from  uveal  melanomas  [22-28].  Cell  lines  from  primary
ciliary  body  and  choroidal  melanomas  have  been
characterized by cellular morphology, relative growth rate,
vasculogenic cord formation, immunohistochemistry, major
histocompatability complex (MHC), and cytogenetic analysis
of  cell  lines  with  karyotype  study  and  determination  of
monosomy  3  status  by  microsatellite  analysis.  Cell  lines
derived from ciliary body and choroidal melanoma metastases
have  been  studied  by  Luyton  et  al.  [25,27]  using  similar
methods including karyotype analysis. Adding an additional
dimension, this report presents analysis of primary choroidal
melanomas  and  their  cell  lines  with  high  resolution
microarrays to compare cytogenetic characteristics and gene
expression profiles.
Figure 2. Comparison of Mapping Array results for chromosomal copy number for primary tumor biopsies and their cell lines, where available.
Copy number variation analysis, as determined by Affymetrix Genotyping Console, showed identical patterns of aberration between primary
tumor biopsies and corresponding cell lines. Gains (green boxes) and losses (red boxes) were largely whole arm in extent. 2± designations
signify a total of 4 or more copies of chromosome 8q were detected. All samples had monosomy 3, 6q loss, 8p loss, multiple gains in 8q, and
16q loss. MEL20–06–045 and MEL20–07–070 also had 6p gain.
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610Figure 3. Comparison of expressional characteristics between primary melanomas and their corresponding cell lines. Normalized expressional
values from Affymetrix GeneChip HG U133 plus 2.0 arrays for 25 genes significantly upregulated in monosomy 3 tumors and 20 genes
significantly down-regulated or silenced in monosomy 3 melanomas compared to melanomas with 6p gain in the absence of chromosome 3
loss were selected to compare expressional variation between primary tumor biopsies and the corresponding cell lines. A: MEL20–06–039;
B: MEL20–07–070; C: MEL20–06–045 cell line is shown in combination with MEL20–06–039 and MEL20–07–070 to provide a comparison
of this cell line’s expressional profile with those for which primary tumor expressional characteristics are known. Probeset identifiers and
genomic locations of the listed genes are detailed in Table 2.
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611Recognition  that  cancer  is  fundamentally  a  genetic
disease emphasizes the importance of precisely characterizing
the cytogenetic and gene expression of primary choroidal
melanomas  and  the  corresponding  cell  lines.  Choroidal
melanoma cell lines with genetic alterations that reflect their
primary  tumor  provide  malleable  in  vitro  models.  These
TABLE 2. GENES UPREGULATED, DOWN-REGULATED, OR SILENCED IN MONOSOMY 3 TUMORS.
Genes significantly upregulated in monosomy 3 tumors
Probe set ID Gene symbol Location
206638_at HTR2B chr2q37.1
229823_at — chr8q22.3
204939_s_at PLN chr6q22.31
206137_at RIMS2 chr8q22.3
206626_x_at SSX1 chrXp11.22
228170_at OLIG1 chr21q22.11
211425_x_at SSX4 chrXp11.23
230650_at — chr8q13.3
205825_at PCSK1 chr5q15
204897_at PTGER4 chr5p13.1
229975_at BMPR1B chr4q22.3
209031_at CADM1 chr11q23.2
212671_s_at HLA-DQA1 chr6p21.32
209496_at RARRES2 chr7q36.1
202158_s_at CUGBP2 chr10p14
227812_at TNFRSF19 chr13q12.12
219895_at FAM70A chrXq24
235061_at PPM1K chr4q22.1
231202_at ALDH1L2 chr12q23.3
202660_at ITPR2 chr12p11.23
235182_at C20orf82 chr20p12.1
243339_at — chr5q33.1
238720_at OMG chr17q11.2
244463_at ADAM23 chr2q33.3
204472_at GEM chr8q22.1
Genes significantly down-regulated or silenced in monosomy 3 tumors
Probe set ID Gene symbol Location
223572_at HHATL chr3p22.1
210809_s_at POSTN chr13q13.3
205799_s_at SLC3A1 chr2p21
231535_x_at ROPN1 chr3q21.1
232054_at PCDH20 chr13q21.31
201839_s_at TACSTD1 chr2p21
232523_at MEGF10 chr5q23.2
205413_at MPPED2 chr11p14.1
203786_s_at TPD52L1 chr6q22.31
238592_at PDLIM3 chr4q35.1
235238_at SHC4 chr15q21.1
218332_at BEX1 chrXq22.1
230303_at SYNPR chr3p14.2
236936_at — chr8p11.23
236300_at — chr12p12.2
242206_at — chr7q11.21
228245_s_at LOC100132881 chr12p13.31
234583_at CHL1 chr3p26.3
207010_at GABRB1 chr4p12
204584_at L1CAM chrXq28
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612models enable mechanistic dissection of melanoma biology,
identification  of  “driver”  genes  and  insight  regarding
therapeutic targets [29].
Strengths of the three cell lines described in this report
for in vitro study of choroidal melanoma biology and testing
of  therapeutic  targets  relate  to  (1)  origin  from  primary
choroidal  melanomas  that  developed  clinical  evidence  of
metastasis <1.5 years after treatment of the primary tumor, (2)
demonstration  of  cellular  propagation  through  at  least  6
passages,  (3)  documentation  of  equivalent  cytogenetic
aberrations  and  similar  gene  expression  patterns  in  the
primary melanomas and in the cell lines at passage 3, and (4)
preservation of cell lines by freezing at passage 3 to provide
highly characterized cell lines for future studies.
Limitations of the three cell lines as surrogates for study
of melanoma biology, metastasis and therapy relate to (1) the
limited but potentially significant differences in chromosomal
aberration and gene expression between primary melanomas
and corresponding cell lines, (2) the likelihood that, with long-
term  propagation  and  multiple  passages,  cell  lines  will
undergo  culture-related  evolution  in  both  chromosomal
structure and gene expression, and (3) recognition that cancer
biology is influenced by the in vivo micro-environment that
is not replicated with in vitro models. However, the fact that
the cell lines differ slightly between themselves may not be as
important  as  having  a  diverse  genetic  background  under
which therapeutic drugs may be tested to determine biologic
pathways in tumor development.
In summary, FNAB of primary choroidal melanomas that
developed clinical metastases resulted in the development of
three  low-passage,  highly  characterized  cell  lines  that
exhibited the chromosomal aberrations and gene expression
profiles present in the primary choroidal melanomas. These
cell lines, with portions frozen beginning at passage 3 and
portions continuing to propagate, provide in vitro models for
study of choroidal melanoma biology, metastasis and therapy.
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